EXEL - Latest News
Exelixis, Inc. (EXEL), operates in Healthcare / Biotechnology, trades on NASDAQ.
Market capitalization stands near $12.89B. Trailing twelve-month P/E ratio is 15.90. Beta to the broader market is 0.39.
The article list below shows the most recent EXEL headlines from major financial news vendors. For options traders, the most actionable items are earnings releases, analyst rating changes, M&A activity, and regulatory filings - each can drive a meaningful repricing of implied volatility and shift dealer hedging flow. Pair the news context with the implied-volatility skew and gamma exposure views to see whether the options market has already priced in the headline.
Recent EXEL Headlines
Prediction: This Stock Could Double By 2031
fool.com - May 15, 2026
Exelixis's main product should continue driving growth through the end of the decade. The company is close to earning approval for a medicine that wi
Exelixis (EXEL) is a Top-Ranked Momentum Stock: Should You Buy?
zacks.com - May 15, 2026
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Exelixis, Inc. (EXEL) Presents at Bank of America Global Healthcare Conference 2026 Transcript
seekingalpha.com - May 12, 2026
Exelixis, Inc.
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in May
businesswire.com - May 7, 2026
ALAMEDA, Calif. --(BUSINESS WIRE)--Exelixis, Inc.
EXEL Q1 Earnings Top Estimates, Colorectal Cancer Drug in Focus
zacks.com - May 6, 2026
EXEL beats Q1 EPS estimates on lower costs and buybacks but misses on revenues; Cabometyx sales lag estimates as pipeline progress and new buybacks st
How News Affects EXEL Options Pricing
Headlines and scheduled events drive implied volatility in two distinct ways. Pre-event, IV typically inflates as uncertainty about the outcome rises; this is the implied-volatility expansion that creates the long-vol setup. Post-event, IV typically contracts sharply as uncertainty resolves; this is IV crush, which makes premium-selling structures profitable when they survive the underlying move. The size of the crush depends on how stretched pre-event IV is relative to the realized move. Track EXEL's implied vs realized volatility over the news cycle to size pre-event vs post-event positioning. For ticker-level dealer positioning context, the gamma exposure view shows whether dealers are positioned to amplify or dampen post-news moves.
Frequently asked EXEL news questions
- What is the latest EXEL news headline?
- The most recent EXEL headline (May 15, 2026) is "Prediction: This Stock Could Double By 2031". The five most recent stories with summaries and publication times are listed above, sourced from major financial news vendors.
- How fresh is the EXEL news on this page?
- News rows refresh roughly every 30 minutes during the trading day. The five most recent headlines are listed in publication-time order. Press releases from the company itself typically appear within minutes of the wire release; third-party reporting may lag by 30-60 minutes depending on the source.
- What EXEL news moves options pricing?
- Three categories move single-name IV most aggressively: scheduled earnings releases (priced into pre-event IV, crushed post-event), unscheduled M&A or strategic announcements (rapid IV expansion, slower decay), and regulatory or legal events (drug-trial readouts, antitrust filings, FDA approvals). Routine news flow (analyst commentary, sector rotation) typically does not move IV meaningfully unless it triggers a cluster of rating changes.
- How can I track unusual EXEL options activity related to news?
- Unusual options activity often precedes news by hours to days; the canonical signals are volume substantially above the trailing average concentrated in a small number of strikes, atypical put/call skew, and aggressive execution (at-the-ask sweeps or block prints). Cross-reference the per-ticker gamma-exposure and volume-history pages with the news flow above to triangulate informed vs uninformed flow.